Biogen Idec Reports Effective Treatment for Alzheimer’s

Researchers for Biogen Idec reported that an experimental drug sharply slowed the decline of mental function in a small clinical trial. The drug, called aducanumab, is designed to remove amyloid plaque in the brain, which is widely believed to be a cause of the dementia in Alzheimer’s disease. The reduction in cognitive decline was above 70% for certain patients. There are concerns about side effects associated with the drug, which includes brain swelling. Biogen hopes to begin larger clinical trials this year. [3/24/15]